By: IPP Bureau
Last updated : June 08, 2021 11:19 am
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Sun Pharma has now acquired the rights to trademarks Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India Limited, with effect from 28th May 2021.
In addition Sun Pharma has also taken a patent license to manufacture and commercialize Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from 28th May 2021.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021.
Under the Transition Supply Agreement, AstraZeneca India will supply Dapagliflozin and the combination of Dapagliflozin with Metformin to Sun Pharma until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.
AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively.